Health Italia SpA (FRA:6I50) Research & Development: €0.00 Mil (TTM As of Jun. 2025)


FRA:6I50 Health Italia SpA FRA:6I50
60 GF Score
Price €296.00
GF Value €141.14
! 4 Warning Signs
View Full Analysis

What is Health Italia SpA Research & Development?

Health Italia SpA FRA:6I50 60 Research & Development is €0.00 Mil as of Jun. 2025. GuruFocus rates FRA:6I50 with a GF Score™ of 60/100 and a GF Value™ of €141.14. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Health Italia SpA's Research & Development for the six months ended in Jun. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 was €0.00 Mil.

Health Italia SpA  (FRA:6I50) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Health Italia SpA Research & Development Related Terms

Health Italia SpA Research & Development Historical Data

* Premium members only.

The historical data trend for Health Italia SpA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Health Italia SpA Research & Development Chart

Health Italia SpA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Health Italia SpA Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:6I50
60GF Score
Health Italia SpA FRA:6I50
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Health Italia SpA Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Health Italia SpA (FRA:6I50) has a Research & Development of €0.00 Mil as of Jun. 2025. Research and development expense is the total cost for research and development activities. View historical data on Health Italia SpA and its competitors.
Is Health Italia SpA's Research & Development too high?
Health Italia SpA's current Research & Development is €0.00 Mil. Overall, Health Italia SpA has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Health Italia SpA's Research & Development compare to UNH and CVS?
Health Italia SpA's Research & Development of €0.00 Mil can be compared against companies in the Healthcare Plans industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Plans company?
A good Research & Development depends on the Healthcare Plans industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Health Italia SpA and its competitors. Health Italia SpA's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Health Italia SpA stock overvalued right now?
Health Italia SpA (FRA:6I50) has a current Research & Development of €0.00 Mil. The stock's GF Value™ is €141.14, compared to a current price of €296.00 — trading 109.7% above its estimated fair value. The current Research & Development is €0.00 Mil. Health Italia SpA's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Health Italia SpA (FRA:6I50), the current Research & Development is €0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Health Italia SpA (FRA:6I50) Overvalued in 2026?

Based on GuruFocus' analysis, Health Italia SpA stock appears to be overvalued. The current stock price of €296.00 is trading 109.7% above its estimated GF Value™ of €141.14.

Key valuation signals for FRA:6I50:

  • Research & Development: €0.00 Mil
  • GF Value™: €141.14 vs. price of €296.00 (109.7% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the FRA:6I50 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Health Italia SpA Business Description

Address Via di Santa Cornelia, 9, Formello, ITA, 00060
Health Italia SpA is an Italy based company engaged in offering integrated healthcare services. It operates in the promotion of integrated and alternative healthcare solutions and provides administrative, liquidation, information technology and consulting services for health funds, health care funds and mutual-aid companies. In addition, the group is also active in the corporate welfare market and manages outsourced flexible benefit welfare plans.
60GF Score

Get the complete analysis for FRA:6I50

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€296.00
Price
€141.14
GF Value